![]() However, treatment patterns and clinical experience of obtaining pCR with dual blockade via pertuzumab and trastuzumab in patients with HER2+ stage II-III EBC have not been assessed extensively in the real-world setting. In neoadjuvant treatments, pertuzumab plus trastuzumab combined with chemotherapy is now recommended as part of the treatment regimen for stage II and III HER2+ EBC. In this trial, the results achieved with trastuzumab were improved with the addition of pertuzumab, reaching pCR rates of 39%. The primary trial supporting the approval of pertuzumab for use in combination with trastuzumab and docetaxel as NST for patients with HER2+ EBC was the phase II NEOSPHERE trial. The humanized monoclonal antibody, pertuzumab, binds HER2 at a different site from that of trastuzumab and prevents HER2 dimerization with other HER family members. With the addition of trastuzumab to chemotherapy as NST, a significant improvement in the pCR rate was observed. In the early 2000s, trastuzumab became an integral part of NST for patients with HER2+ EBC. Nowadays, anti-HER2 therapy paired with chemotherapy is an essential component of NST in the management of HER2+ early breast cancer (EBC). Neoadjuvant systemic therapy (NST) has many advantages since it serves as a tool for in vitro assessment of response, it allows less aggressive surgery, more breast-conserving therapy, and early treatment of micro-metastatic disease. ![]() The rate of breast-conserving surgery was significantly increased. None of the variables were independent predictors of DFS.Ĭonclusion: The pCR rate achieved in our study demonstrates the reproducibility of trial data in a real-world population. Ki67 expression and neutrophil-to-lymphocyte ratio (NLR) significantly predicted pCR. As a result of NST a significant increase of conservative breast surgeries (33% vs. The majority of the patients (95%) received a sequence of anthracycline-based chemotherapy followed by docetaxel. The study included women with a median age of 50.3 years. Results: Eighty-two patients were included in the study treated in 8 cancer centers in Hungary between March 2015 and January 2020. Data were collected from patients’ medical records. Methods: This was a multicentre, retrospective, observational study in patients with stage II and III HER2+ early breast cancer who received pertuzumab and trastuzumab-based NST. The secondary and tertiary objective was to investigate the impact of neoadjuvant systemic therapy (NST) on performing breast-conserving surgery and survival data. The aim of this study was to determine the pCR rate obtained with dual HER2 blockade in routine clinical practice. Purpose: The neoadjuvant use of pertuzumab and trastuzumab with chemotherapy improves the pathologic complete response (pCR) in early HER2+ breast cancer. 10Department of Thoracic and Abdominal Tumors and Clinical Pharmacology, National Institute of Oncology, Budapest, Hungary.9Department of Oncology, Faculty of Medicine, Semmelweis University, Budapest, Hungary.8Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary.7Oncoradiological Center, Bács-Kiskun County Hospital, Kecskemét, Hungary.6Department of Oncology, Somogy County Kaposi Mór Hospital, Kaposvár, Hungary.5Department of Medical Oncology, Zala County Hospital, Zalaegerszeg, Hungary.4Department of Oncology, Jász-Nagykun-Szolnok Hetényi County Hospital, Szolnok, Hungary.3Department of Oncoradiology, Uzsoki Teaching Hospital, Budapest, Hungary.2Department of Oncotherapy, Faculty of Medicine, University of Szeged, Szeged, Hungary.1Department of Medical Oncology, Szent Margit Hospital, Budapest, Hungary.Katalin Boér 1, Zsuzsanna Kahán 2, László Landherr 3, Tibor Csőszi 4, Károly Máhr 5, Ágnes Ruzsa 6, Zsolt Horváth 7, Barna Budai 8 and Gábor Rubovszky 9,10*
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |